Tags

Type your tag names separated by a space and hit enter

Serum type I interferon activity is dependent on maternal diagnosis in anti-SSA/Ro-positive mothers of children with neonatal lupus.
Arthritis Rheum. 2008 Feb; 58(2):541-6.AR

Abstract

OBJECTIVE

The type I interferon (IFN) pathway is activated in many patients with systemic lupus erythematosus (SLE), and high serum levels of IFN are associated with anti-SSA/Ro autoantibodies. To investigate the clinical features associated with type I IFN production in vivo, we compared serum IFN activity in individuals with anti-SSA/Ro antibodies who were asymptomatic with that in individuals with clinical manifestations of SLE or Sjögren's syndrome (SS).

METHODS

Antibody-positive sera from 84 mothers of children with manifestations of neonatal lupus were studied for type I IFN activity, using a functional reporter cell assay. Maternal health status was characterized as asymptomatic, SS, SLE, pauci-SLE, or pauci-SS, based on a screening questionnaire, telephone interview, and review of medical records. The prefix "pauci-" indicates symptoms insufficient for a formal classification of the disease.

RESULTS

Only 4% of asymptomatic mothers had high serum type I IFN activity, compared with 73% with pauci-SLE (P = 5.7 x 10(-5)), 35% with SLE (P = 0.011), and 32% of patients with SS (P = 0.032). One of the 4 patients with pauci-SS had high levels of IFN. The majority of patients for whom longitudinal data were available had stable type I IFN activity over time, and changes in IFN activity were not clearly accompanied by changes in the clinical diagnosis.

CONCLUSION

Patients with SLE, patients with pauci-SLE, and patients with SS are more likely to have high serum IFN activity than asymptomatic individuals with SSA/Ro autoantibodies, suggesting that these autoantibodies are insufficient for activation of the type I IFN pathway, and that disease-specific factors are important for type I IFN generation in vivo.

Authors+Show Affiliations

University of Chicago, Section of Rheumatology, Chicago, Illinois 60637, USA. tniewold@medicine.bsd.uchicago.eduNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18240214

Citation

Niewold, Timothy B., et al. "Serum Type I Interferon Activity Is Dependent On Maternal Diagnosis in anti-SSA/Ro-positive Mothers of Children With Neonatal Lupus." Arthritis and Rheumatism, vol. 58, no. 2, 2008, pp. 541-6.
Niewold TB, Rivera TL, Buyon JP, et al. Serum type I interferon activity is dependent on maternal diagnosis in anti-SSA/Ro-positive mothers of children with neonatal lupus. Arthritis Rheum. 2008;58(2):541-6.
Niewold, T. B., Rivera, T. L., Buyon, J. P., & Crow, M. K. (2008). Serum type I interferon activity is dependent on maternal diagnosis in anti-SSA/Ro-positive mothers of children with neonatal lupus. Arthritis and Rheumatism, 58(2), 541-6. https://doi.org/10.1002/art.23191
Niewold TB, et al. Serum Type I Interferon Activity Is Dependent On Maternal Diagnosis in anti-SSA/Ro-positive Mothers of Children With Neonatal Lupus. Arthritis Rheum. 2008;58(2):541-6. PubMed PMID: 18240214.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Serum type I interferon activity is dependent on maternal diagnosis in anti-SSA/Ro-positive mothers of children with neonatal lupus. AU - Niewold,Timothy B, AU - Rivera,Tania L, AU - Buyon,Jill P, AU - Crow,Mary K, PY - 2008/2/2/pubmed PY - 2008/4/9/medline PY - 2008/2/2/entrez SP - 541 EP - 6 JF - Arthritis and rheumatism JO - Arthritis Rheum. VL - 58 IS - 2 N2 - OBJECTIVE: The type I interferon (IFN) pathway is activated in many patients with systemic lupus erythematosus (SLE), and high serum levels of IFN are associated with anti-SSA/Ro autoantibodies. To investigate the clinical features associated with type I IFN production in vivo, we compared serum IFN activity in individuals with anti-SSA/Ro antibodies who were asymptomatic with that in individuals with clinical manifestations of SLE or Sjögren's syndrome (SS). METHODS: Antibody-positive sera from 84 mothers of children with manifestations of neonatal lupus were studied for type I IFN activity, using a functional reporter cell assay. Maternal health status was characterized as asymptomatic, SS, SLE, pauci-SLE, or pauci-SS, based on a screening questionnaire, telephone interview, and review of medical records. The prefix "pauci-" indicates symptoms insufficient for a formal classification of the disease. RESULTS: Only 4% of asymptomatic mothers had high serum type I IFN activity, compared with 73% with pauci-SLE (P = 5.7 x 10(-5)), 35% with SLE (P = 0.011), and 32% of patients with SS (P = 0.032). One of the 4 patients with pauci-SS had high levels of IFN. The majority of patients for whom longitudinal data were available had stable type I IFN activity over time, and changes in IFN activity were not clearly accompanied by changes in the clinical diagnosis. CONCLUSION: Patients with SLE, patients with pauci-SLE, and patients with SS are more likely to have high serum IFN activity than asymptomatic individuals with SSA/Ro autoantibodies, suggesting that these autoantibodies are insufficient for activation of the type I IFN pathway, and that disease-specific factors are important for type I IFN generation in vivo. SN - 0004-3591 UR - https://www.unboundmedicine.com/medline/citation/18240214/Serum_type_I_interferon_activity_is_dependent_on_maternal_diagnosis_in_anti_SSA/Ro_positive_mothers_of_children_with_neonatal_lupus_ L2 - https://doi.org/10.1002/art.23191 DB - PRIME DP - Unbound Medicine ER -